fibromyalgia and glp 1 GLP-1s May Ease Symptom Burden in Patients With Antiobesity medications in rheumatology. Quo

GSH From Antioxidant to Post-Translational Modifier (PMC, 2016) S-Glutathionylation as a Major Redox Signalling Mechanism A review published in PMC, authored by a leading researcher in the field, documented GSHs evolution in the scientific literature from a simple antioxidant to a key post-translational modifier through S-glutathionylation the reversible formation of mixed disulfides between GSH and protein cysteine residues

Thilo Drk-Bousset for the possibility to use the BiomarkHD and IFC Controller HX at his molecular gynaecology research group at Hannover Medical School, and Peter Schrmann for excellent instruction and technical support

For a closer look at how that affects treatment handling, see our article on what compounded GLP-1 is and how it works

A compounded product is considered essentially a copy if it has the same API as a commercially available drug in the same, similar, or easily substitutable strength, and can be used by the same route of administration, unless the prescriber documents a patient-specific change that produces a significant difference

PMID: 28830317

Alpha-lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta-analysis of randomised placebo-controlled clinical trials